08/20/2025 4:28 PM | Frazier Life Sciences X, L.P. (Filed by) NewAmsterdam Pharma Co N.V. (Subject) NewAmsterdam Pharma (Subject)
| Form SCHEDULE 13D/A | |
08/18/2025 7:00 AM | NewAmsterdam Pharma Co N.V. (Filer) NewAmsterdam Pharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
08/13/2025 11:56 AM | Capital World Investors (Filed by) NewAmsterdam Pharma Co N.V. (Subject) NewAmsterdam Pharma (Subject)
| Form SCHEDULE 13G/A | |
08/12/2025 3:30 PM | Forbion Capital Fund IV Cooperatief U.A. (Filed by) NewAmsterdam Pharma Co N.V. (Subject) NewAmsterdam Pharma (Subject)
| Form SCHEDULE 13D/A | |
08/06/2025 6:00 AM | NewAmsterdam Pharma Co N.V. (Filer) NewAmsterdam Pharma (Filer)
| Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
08/06/2025 6:00 AM | NewAmsterdam Pharma Co N.V. (Filer) NewAmsterdam Pharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
07/30/2025 7:25 AM | NewAmsterdam Pharma Co N.V. (Filer) NewAmsterdam Pharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
07/14/2025 3:12 PM | NAP PoolCo B.V. (Reporting) NewAmsterdam Pharma Co N.V. (Subject) NewAmsterdam Pharma (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
07/11/2025 3:25 PM | NewAmsterdam Pharma Co N.V. (Filer) NewAmsterdam Pharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
06/26/2025 6:41 PM | NewAmsterdam Pharma Co N.V. (Issuer) NewAmsterdam Pharma (Issuer) Topper James N (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/18/2025 3:42 PM | NewAmsterdam Pharma Co N.V. (Issuer) NewAmsterdam Pharma (Issuer) Topper James N (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
Get the Latest News and Ratings for NAMSW and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for NewAmsterdam Pharma and its competitors with MarketBeat's FREE daily newsletter.
|
06/18/2025 3:50 PM | Kling Douglas F (Reporting) NewAmsterdam Pharma Co N.V. (Issuer) NewAmsterdam Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
06/18/2025 11:31 AM | NAP PoolCo B.V. (Reporting) NewAmsterdam Pharma Co N.V. (Subject) NewAmsterdam Pharma (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
06/11/2025 8:00 AM | NewAmsterdam Pharma Co N.V. (Filer) NewAmsterdam Pharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
06/09/2025 6:28 AM | NewAmsterdam Pharma Co N.V. (Filer) NewAmsterdam Pharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
06/06/2025 3:35 PM | NewAmsterdam Pharma Co N.V. (Filer) NewAmsterdam Pharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
05/15/2025 3:40 PM | Kling Douglas F (Reporting) NewAmsterdam Pharma Co N.V. (Subject) NewAmsterdam Pharma (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
05/13/2025 10:44 AM | Capital World Investors (Filed by) NewAmsterdam Pharma Co N.V. (Subject) NewAmsterdam Pharma (Subject)
| Form SCHEDULE 13G | |
05/08/2025 3:28 PM | NewAmsterdam Pharma Co N.V. (Filer) NewAmsterdam Pharma (Filer)
| Form ARS | |
05/08/2025 7:00 AM | NewAmsterdam Pharma Co N.V. (Filer) NewAmsterdam Pharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
05/08/2025 7:00 AM | NewAmsterdam Pharma Co N.V. (Filer) NewAmsterdam Pharma (Filer)
| Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
05/07/2025 6:36 AM | NewAmsterdam Pharma Co N.V. (Filer) NewAmsterdam Pharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
04/21/2025 4:41 PM | LANGE LOUIS G (Reporting) NewAmsterdam Pharma Co N.V. (Issuer) NewAmsterdam Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
04/17/2025 4:34 PM | Gulfo Adele M. (Reporting) NewAmsterdam Pharma Co N.V. (Issuer) NewAmsterdam Pharma (Issuer)
| Form 3 Initial statement of beneficial ownership of securities | |
04/17/2025 4:36 PM | Gulfo Adele M. (Reporting) NewAmsterdam Pharma Co N.V. (Issuer) NewAmsterdam Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
04/17/2025 4:41 PM | Kling Douglas F (Reporting) NewAmsterdam Pharma Co N.V. (Issuer) NewAmsterdam Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
04/17/2025 4:06 PM | NewAmsterdam Pharma Co N.V. (Filer) NewAmsterdam Pharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
03/28/2025 4:36 PM | NewAmsterdam Pharma Co N.V. (Issuer) NewAmsterdam Pharma (Issuer) Topper James N (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/28/2025 4:18 PM | Kling Douglas F (Reporting) NewAmsterdam Pharma Co N.V. (Issuer) NewAmsterdam Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/28/2025 4:20 PM | Kastelein Johannes Jacob Pieter (Reporting) NewAmsterdam Pharma Co N.V. (Issuer) NewAmsterdam Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/28/2025 4:24 PM | LANGE LOUIS G (Reporting) NewAmsterdam Pharma Co N.V. (Issuer) NewAmsterdam Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/28/2025 4:29 PM | Kooij Louise Frederika (Reporting) NewAmsterdam Pharma Co N.V. (Issuer) NewAmsterdam Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/26/2025 5:19 PM | Davidson Michael H. (Reporting) NewAmsterdam Pharma Co N.V. (Subject) NewAmsterdam Pharma (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
03/26/2025 5:00 PM | Kling Douglas F (Reporting) NewAmsterdam Pharma Co N.V. (Subject) NewAmsterdam Pharma (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
03/26/2025 3:27 PM | Kastelein Johannes Jacob Pieter (Reporting) NewAmsterdam Pharma Co N.V. (Issuer) NewAmsterdam Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/19/2025 4:29 PM | Kling Douglas F (Reporting) NewAmsterdam Pharma Co N.V. (Issuer) NewAmsterdam Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/10/2025 11:15 PM | NewAmsterdam Pharma Co N.V. (Filer) NewAmsterdam Pharma (Filer)
| Form EFFECT | |
03/10/2025 3:52 PM | NewAmsterdam Pharma Co N.V. (Filer) NewAmsterdam Pharma (Filer)
| Form 424B3 | |
03/06/2025 4:32 PM | NewAmsterdam Pharma Co N.V. (Issuer) NewAmsterdam Pharma (Issuer) Topper James N (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/05/2025 5:10 PM | Kooij Louise Frederika (Reporting) NewAmsterdam Pharma Co N.V. (Issuer) NewAmsterdam Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
03/04/2025 5:54 PM | Kooij Louise Frederika (Reporting) NewAmsterdam Pharma Co N.V. (Subject) NewAmsterdam Pharma (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
When the levee breaks (Ad) The U.S. Treasury just confirmed it plans to borrow $1.01 trillion this quarter—nearly double what was projected. According to Porter Stansberry, this is panic-level borrowing… and a clear sign we’re nearing America’s financial breaking point.
In his latest emergency briefing, Porter outlines why the cracks in our system are widening fast—and how Trump’s policies may be accelerating the collapse. More importantly, he reveals three moves you can make now to protect and potentially grow your wealth before the levee breaks. Click here to watch the urgent broadcast and get ahead of what’s coming. |
02/28/2025 4:06 PM | NewAmsterdam Pharma Co N.V. (Filer) NewAmsterdam Pharma (Filer)
| Form S-3 Registration statement under Securities Act of 1933 | |
02/26/2025 7:00 AM | NewAmsterdam Pharma Co N.V. (Filer) NewAmsterdam Pharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
02/26/2025 7:00 AM | NewAmsterdam Pharma Co N.V. (Filer) NewAmsterdam Pharma (Filer)
| Form 10-K Annual report pursuant to Section 13 or 15(d) | |
02/20/2025 4:24 PM | Kling Douglas F (Reporting) NewAmsterdam Pharma Co N.V. (Issuer) NewAmsterdam Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
02/14/2025 5:42 PM | NewAmsterdam Pharma Co N.V. (Subject) NewAmsterdam Pharma (Subject) RA CAPITAL MANAGEMENT, L.P. (Filed by)
| Form SCHEDULE 13G/A | |
01/31/2025 4:00 PM | Kling Douglas F (Reporting) NewAmsterdam Pharma Co N.V. (Issuer) NewAmsterdam Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/29/2025 4:25 PM | NewAmsterdam Pharma Co N.V. (Issuer) NewAmsterdam Pharma (Issuer) Somaiya Mayur Ian (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/29/2025 4:16 PM | Kling Douglas F (Reporting) NewAmsterdam Pharma Co N.V. (Issuer) NewAmsterdam Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/27/2025 4:09 PM | Kling Douglas F (Reporting) NewAmsterdam Pharma Co N.V. (Subject) NewAmsterdam Pharma (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
01/27/2025 3:52 PM | NewAmsterdam Pharma Co N.V. (Subject) NewAmsterdam Pharma (Subject) Somaiya Mayur Ian (Reporting)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
01/10/2025 3:26 PM | NAP PoolCo B.V. (Reporting) NewAmsterdam Pharma Co N.V. (Subject) NewAmsterdam Pharma (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
01/10/2025 7:27 AM | NewAmsterdam Pharma Co N.V. (Filer) NewAmsterdam Pharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
01/08/2025 4:58 PM | NewAmsterdam Pharma Co N.V. (Issuer) NewAmsterdam Pharma (Issuer) van der Kamp Hilde Johanna (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/08/2025 5:03 PM | Lewis William (Reporting) NewAmsterdam Pharma Co N.V. (Issuer) NewAmsterdam Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/08/2025 5:08 PM | McKenna Mark C. (Reporting) NewAmsterdam Pharma Co N.V. (Issuer) NewAmsterdam Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/08/2025 5:09 PM | NewAmsterdam Pharma Co N.V. (Issuer) NewAmsterdam Pharma (Issuer) Smither John W (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/08/2025 4:57 PM | LANGE LOUIS G (Reporting) NewAmsterdam Pharma Co N.V. (Issuer) NewAmsterdam Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/07/2025 4:21 PM | Kastelein Johannes Jacob Pieter (Reporting) NewAmsterdam Pharma Co N.V. (Issuer) NewAmsterdam Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/07/2025 4:21 PM | Davidson Michael H. (Reporting) NewAmsterdam Pharma Co N.V. (Issuer) NewAmsterdam Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/07/2025 4:21 PM | Kooij Louise Frederika (Reporting) NewAmsterdam Pharma Co N.V. (Issuer) NewAmsterdam Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/07/2025 4:08 PM | NewAmsterdam Pharma Co N.V. (Issuer) NewAmsterdam Pharma (Issuer) Somaiya Mayur Ian (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/07/2025 4:10 PM | Kling Douglas F (Reporting) NewAmsterdam Pharma Co N.V. (Issuer) NewAmsterdam Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/07/2025 4:12 PM | JONES WILLIAM A JR (Reporting) NewAmsterdam Pharma Co N.V. (Issuer) NewAmsterdam Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/07/2025 3:29 PM | NewAmsterdam Pharma Co N.V. (Filer) NewAmsterdam Pharma (Filer)
| Form S-8 Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
01/06/2025 4:57 PM | Kling Douglas F (Reporting) NewAmsterdam Pharma Co N.V. (Issuer) NewAmsterdam Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/06/2025 4:48 PM | Kastelein Johannes Jacob Pieter (Reporting) NewAmsterdam Pharma Co N.V. (Issuer) NewAmsterdam Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/06/2025 4:51 PM | JONES WILLIAM A JR (Reporting) NewAmsterdam Pharma Co N.V. (Issuer) NewAmsterdam Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/06/2025 4:53 PM | NewAmsterdam Pharma Co N.V. (Issuer) NewAmsterdam Pharma (Issuer) Somaiya Mayur Ian (Reporting)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/06/2025 4:54 PM | Audet Juliette Berangere (Reporting) NewAmsterdam Pharma Co N.V. (Issuer) NewAmsterdam Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/06/2025 4:56 PM | Kooij Louise Frederika (Reporting) NewAmsterdam Pharma Co N.V. (Issuer) NewAmsterdam Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
01/02/2025 3:15 PM | Forbion Capital Fund IV Cooperatief U.A. (Reporting) Forbion Growth Management B.V. (Reporting) Forbion Growth Opportunities Fund I Cooperatief U.A. (Reporting) Forbion IV Management B.V. (Reporting) ForGrowth NAP B.V. (Reporting) NewAmsterdam Pharma Co N.V. (Issuer) NewAmsterdam Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
12/30/2024 3:15 PM | Forbion Capital Fund IV Cooperatief U.A. (Reporting) Forbion Growth Management B.V. (Reporting) Forbion Growth Opportunities Fund I Cooperatief U.A. (Reporting) Forbion IV Management B.V. (Reporting) ForGrowth NAP B.V. (Reporting) NewAmsterdam Pharma Co N.V. (Issuer) NewAmsterdam Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
12/26/2024 3:15 PM | Forbion Capital Fund IV Cooperatief U.A. (Reporting) Forbion Growth Management B.V. (Reporting) Forbion Growth Opportunities Fund I Cooperatief U.A. (Reporting) Forbion IV Management B.V. (Reporting) ForGrowth NAP B.V. (Reporting) NewAmsterdam Pharma Co N.V. (Issuer) NewAmsterdam Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
12/20/2024 3:25 PM | Forbion Capital Fund IV Cooperatief U.A. (Reporting) Forbion Growth Management B.V. (Reporting) Forbion Growth Opportunities Fund I Cooperatief U.A. (Reporting) Forbion IV Management B.V. (Reporting) ForGrowth NAP B.V. (Reporting) NewAmsterdam Pharma Co N.V. (Issuer) NewAmsterdam Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
12/18/2024 3:15 PM | Forbion Capital Fund IV Cooperatief U.A. (Reporting) Forbion Growth Management B.V. (Reporting) Forbion Growth Opportunities Fund I Cooperatief U.A. (Reporting) Forbion IV Management B.V. (Reporting) ForGrowth NAP B.V. (Reporting) NewAmsterdam Pharma Co N.V. (Issuer) NewAmsterdam Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
12/17/2024 4:35 PM | BCLS II Investco, LP (Filed by) NewAmsterdam Pharma Co N.V. (Subject) NewAmsterdam Pharma (Subject)
| Form SC 13D/A | |
12/17/2024 4:05 PM | Bain Capital Life Sciences Fund II, L.P. (Reporting) Bain Capital Life Sciences Fund III, L.P. (Reporting) Bain Capital Life Sciences III General Partner, LLC (Reporting) Bain Capital Life Sciences Investors II, LLC (Reporting) Bain Capital Life Sciences Investors, LLC (Reporting) BCIP Life Sciences Associates, LP (Reporting) BCLS Fund III Investments GP, LLC (Reporting) BCLS Fund III Investments, LP (Reporting) BCLS II Investco , LLC (0001819101) (Reporting) BCLS II Investco, LP (Reporting) NewAmsterdam Pharma Co N.V. (Issuer) NewAmsterdam Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
12/17/2024 3:00 PM | Forbion Capital Fund IV Cooperatief U.A. (Filed by) NewAmsterdam Pharma Co N.V. (Subject) NewAmsterdam Pharma (Subject)
| Form SC 13D/A | |
12/17/2024 9:28 AM | Frazier Life Sciences X, L.P. (Filed by) NewAmsterdam Pharma Co N.V. (Subject) NewAmsterdam Pharma (Subject)
| Form SC 13D/A | |
12/16/2024 3:15 PM | Forbion Capital Fund IV Cooperatief U.A. (Reporting) Forbion Growth Management B.V. (Reporting) Forbion Growth Opportunities Fund I Cooperatief U.A. (Reporting) Forbion IV Management B.V. (Reporting) ForGrowth NAP B.V. (Reporting) NewAmsterdam Pharma Co N.V. (Issuer) NewAmsterdam Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
12/13/2024 7:28 AM | NewAmsterdam Pharma Co N.V. (Filer) NewAmsterdam Pharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
12/13/2024 5:33 AM | NewAmsterdam Pharma Co N.V. (Filer) NewAmsterdam Pharma (Filer)
| Form 424B5 | |
12/12/2024 3:15 PM | Forbion Capital Fund IV Cooperatief U.A. (Reporting) Forbion Growth Management B.V. (Reporting) Forbion Growth Opportunities Fund I Cooperatief U.A. (Reporting) Forbion IV Management B.V. (Reporting) ForGrowth NAP B.V. (Reporting) NewAmsterdam Pharma Co N.V. (Issuer) NewAmsterdam Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
12/11/2024 6:57 PM | NewAmsterdam Pharma Co N.V. (Filer) NewAmsterdam Pharma (Filer)
| Form S-3MEF | |
12/10/2024 3:48 PM | NewAmsterdam Pharma Co N.V. (Filer) NewAmsterdam Pharma (Filer)
| Form 424B5 | |
12/10/2024 6:24 AM | NewAmsterdam Pharma Co N.V. (Filer) NewAmsterdam Pharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
11/20/2024 6:07 AM | NewAmsterdam Pharma Co N.V. (Filer) NewAmsterdam Pharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
11/15/2024 3:29 PM | Forbion Capital Fund IV Cooperatief U.A. (Filed by) NewAmsterdam Pharma Co N.V. (Subject) NewAmsterdam Pharma (Subject)
| Form SC 13D/A | |
11/14/2024 4:46 PM | NewAmsterdam Pharma Co N.V. (Subject) NewAmsterdam Pharma (Subject) RA CAPITAL MANAGEMENT, L.P. (Filed by)
| Form SC 13G/A | |
11/06/2024 7:00 AM | NewAmsterdam Pharma Co N.V. (Filer) NewAmsterdam Pharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
Elon Musk’s New Technology (Ad) Elon Musk is building something in Memphis that could eclipse even Tesla and SpaceX. At the heart of it is a new AI supercomputer—what one industry CEO calls “the most powerful in the world.” Musk says this tech will drive the next wave of American innovation.
You can’t invest in the supercomputer directly—but there’s a backdoor way to access the company powering it. It’s smaller than Tesla or Nvidia, but both rely on it for future growth. Get the full details on the AI company behind Musk’s next big move. |
11/06/2024 7:00 AM | NewAmsterdam Pharma Co N.V. (Filer) NewAmsterdam Pharma (Filer)
| Form 10-Q General form for quarterly reports under Section 13 or 15(d) | |
10/28/2024 7:02 AM | NewAmsterdam Pharma Co N.V. (Filer) NewAmsterdam Pharma (Filer)
| Form 20-F/A | |
10/18/2024 3:51 PM | NewAmsterdam Pharma Co N.V. (Filer) NewAmsterdam Pharma (Filer)
| Form 8-K Current report pursuant to Section 13 or 15(d) | |
10/11/2024 4:01 PM | Davidson Michael H. (Reporting) NewAmsterdam Pharma Co N.V. (Issuer) NewAmsterdam Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
10/01/2024 4:23 PM | Kooij Louise Frederika (Reporting) NewAmsterdam Pharma Co N.V. (Issuer) NewAmsterdam Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |
10/01/2024 4:12 PM | Kooij Louise Frederika (Reporting) NewAmsterdam Pharma Co N.V. (Subject) NewAmsterdam Pharma (Subject)
| Form 144 Notice of proposed sale of securities pursuant to Rule 144 | |
09/30/2024 4:22 PM | Audet Juliette Berangere (Reporting) NewAmsterdam Pharma Co N.V. (Issuer) NewAmsterdam Pharma (Issuer)
| Form 4 Statement of changes in beneficial ownership of securities | |